Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
2024年6月25日 - 9:00PM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
radiopharma company focused on developing innovative treatments for
cancer patients, today announced that its abstract titled
“Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for
Imaging and Treatment of Solid Tumors” has been accepted as a
“Top-Rated Oral Presentation” within the Scientific Program of the
European Association of Nuclear Medicine (EANM) 2024 Annual
Congress to be held on October 19-23, 2024 in Hamburg, Germany.
Monopar’s abstract details its MNPR-101-RIT, a novel
first-in-class radio-immuno-therapeutic program that targets
cancers expressing the urokinase plasminogen activator receptor
(uPAR), including triple-negative breast, colorectal, and
pancreatic cancers. The Company’s preclinical data demonstrate
compelling and durable anti-tumor benefits with MNPR-101 conjugated
to therapeutic radioisotopes, including lutetium-177 (Lu-177) and
actinium-225 (Ac-225).
“We are honored by the recognition of our MNPR-101-RIT abstract
at EANM’24,” said Chandler Robinson, MD, CEO of Monopar
Therapeutics. “This selection underscores the potential of our
uPAR-targeted therapy and the interest around uPAR as a potential
new target for radiopharma treatment.”
Monopar recently initiated its MNPR-101-Zr first-in-human Phase
1 imaging and dosimetry clinical trial in advanced cancer patients.
Further information about this trial is available at
www.ClinicalTrials.gov under study identifier
NCT06337084.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical
company focused on developing innovative treatments for cancer
patients, including Phase 1-stage MNPR-101-Zr for imaging advanced
cancers and late preclinical-stage MNPR-101
radio-immuno-therapeutic (RIT) for the treatment of advanced
cancers, as well as early development programs against solid
cancers. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Examples of these forward-looking statements
include statements concerning: the Company’s preclinical data
demonstrating compelling and durable anti-tumor benefits with
MNPR-101 conjugated to therapeutic radioisotopes, including
lutetium-177 (Lu-177) and actinium-225 (Ac-225); and that the
selection of Monopar’s abstract underscores the potential of its
uPAR-targeted therapy and the interest around uPAR as a potential
new target for radiopharma treatment. The forward-looking
statements involve risks and uncertainties including, but not
limited to: the recently initiated first-in-human Phase 1 imaging
and dosimetry clinical trial in advanced cancer patients with
MNPR-101-Zr may not yield satisfactory results, if at all; that
future preclinical or clinical data will not be as promising as the
data to date; not receiving regulatory clearance to proceed into
human clinical trials for MNPR-101-RIT; that MNPR-101-Zr and/or
MNPR-101-RIT may cause unexpected serious adverse effects in
humans; and the significant general risks and uncertainties
surrounding the research, development, regulatory approval, and
commercialization of imaging agents and therapeutics. Actual
results may differ materially from those expressed or implied by
such forward-looking statements. Risks are described more fully in
Monopar's filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Monopar undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.
Any forward-looking statements contained in this press release
represent Monopar’s views only as of the date hereof and should not
be relied upon as representing its views as of any subsequent
date.
CONTACT:
Monopar Therapeutics Inc. Investor Relations
Kim R. TsuchimotoChief Financial Officerkimtsu@monopartx.com
Follow Monopar on social media for updates:Twitter:
@MonoparTx LinkedIn: Monopar Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
過去 株価チャート
から 5 2024 まで 6 2024
Monopar Therapeutics (NASDAQ:MNPR)
過去 株価チャート
から 6 2023 まで 6 2024